Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amrita Krishnan

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Blood|July 9, 2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee, Stephen Forman, Arturo Molina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
Blood Advances|October 23, 2020
Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumabAmrita Krishnan, Vikram Adhikarla, Erasmus K Poku, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 StudyThomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
JCI Insight|January 19, 2021
CD84 is a regulator of the immunosuppressive microenvironment in multiple myelomaHadas Lewinsky, Emine G Gunes, Keren David, et al.
Targeted Oncology|September 15, 2023
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.
Leukemia|April 17, 2020
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targetingDomenico Viola, Ada Dona, Enrico Caserta, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 20, 2010
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trialPaul G Richardson, Robert J Soiffer, Joseph H Antin, et al.
Blood|June 22, 2011
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisShaji Kumar, Mei-Jie Zhang, Peigang Li, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 7, 2016
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR AnalysisEmma C Scott, Parameswaran Hari, Manish Sharma, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Blood|July 9, 2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee, Stephen Forman, Arturo Molina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
Blood Advances|October 23, 2020
Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumabAmrita Krishnan, Vikram Adhikarla, Erasmus K Poku, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 StudyThomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
JCI Insight|January 19, 2021
CD84 is a regulator of the immunosuppressive microenvironment in multiple myelomaHadas Lewinsky, Emine G Gunes, Keren David, et al.
Targeted Oncology|September 15, 2023
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.
Leukemia|April 17, 2020
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targetingDomenico Viola, Ada Dona, Enrico Caserta, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 20, 2010
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trialPaul G Richardson, Robert J Soiffer, Joseph H Antin, et al.
Blood|June 22, 2011
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisShaji Kumar, Mei-Jie Zhang, Peigang Li, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 7, 2016
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR AnalysisEmma C Scott, Parameswaran Hari, Manish Sharma, et al.
Pageof 12